• Predictheon

  Participated · Equity · Apr 2026

  Predictheon is developing an artificial intelligence platform aimed at giving anesthesiologists a single screen with the information they need and the ability to warn of imminent complications. The company was founded by Dr. Pedro Gambús together with physicians Sebastián Jaramillo and Jose Fernando Valencia, and is led by CEO Eva Gubern. Current plans focus on obtaining regulatory approval, initiating clinical trials and running additional pilot deployments, with a target of reaching a minimum market state around 2028. The startup has a small team of nine people and expects modest headcount growth to about 10–11 this year. Financially, it recently secured €1.8 million to fund these next development and commercialization steps. Predictheon is already engaging in discussions with large medical-equipment companies about potential partnerships, distribution deals or exits, and the company does not intend to handle a global commercial strategy entirely on its own.

• TeiaCare

  Participated · Equity · Apr 2026

  TeiaCare develops a proprietary platform, Ancelia, that uses optical sensors and artificial intelligence to monitor residential care environments and convert data into actionable insights for care staff. The company targets nursing homes, rehabilitation centres, and dementia care units and currently serves more than 150 clients across over 200 facilities, covering about 75,000 residents. Founded in 2018 by Guido Magrin and Luca Iozzia, TeiaCare is expanding its product scope toward broader healthcare and home care settings. With the new funding, it plans to scale its business model, enhance its Data, Spatial, and Care Intelligence capabilities, and begin international expansion focused initially on France and Spain.

• Health Lean Analytics

  Participated · Seed · Mar 2026

  Health Lean Analytics develops solutions that passively and automatically capture clinical and operational hospital data in real time and integrates that information with existing hospital systems. Its platform uses IoT, advanced analytics and AI to interpret patterns, anticipate deviations and recommend role-specific actions to improve safety, efficiency and resource management—with a particular focus on the surgical suite. The company positions its technology to reduce errors, lower operational and material costs, free up clinical staff time, and optimise surgical capacity. HLA’s solutions unify data on patients, surgical materials, medications, operating room usage, and equipment to provide traceable and reliable information. Following the latest financing, HLA plans to accelerate R&D and pursue commercial deployment in the United States within the next 12 months, supported by Novanta as a strategic partner and board representative.

• Sycai Technologies

  Participated · Equity · Jan 2025

  Sycai Medical builds an AI-driven digital medical device that scans medical imaging to detect early cancers and premalignant lesions in the abdomen without invasive tests. The software analyzes every imaging test, even those performed for unrelated reasons, to automate patient monitoring and to scan low‑symptom patients for lesions. For oncologic patients it helps clinicians quantify treatment response and it aims to better define benign lesions that will never develop into cancer. The company is based in Barcelona and is active in Spain and Italy. Sycai is undergoing a transformation from a product‑driven to a business‑driven organization following MDR approval and the initiation of commercial activities. The firm recently raised funding to further develop its technology and support commercialization. Sycai Medical develops an AI-powered medical software that analyzes CT images to detect early pancreatic lesions and estimate their likelihood of progressing to cancer. Its algorithm highlights areas of concern on scans and provides alerts to radiologists to accelerate diagnosis; the diagnostic method has been patented. The company plans to commercialize via direct sales to clinics and hospitals and by licensing its technology into PACS devices, and already has preagreements with several companies. In the near term Sycai intends to expand the technology to other abdominal cancers, notably liver and kidney. Financially, Sycai raised €780,000 in March 2022 and previously received a €75,000 Startup Capital grant from ACCIÓ to support early development. The new funding will be used to complete final clinical trials and secure the CE mark; the company was founded in 2020 and has six employees in Barcelona.

• MiMARK

  Participated · Seed · Nov 2023

  MiMARK Diagnostics, a femtech spin-off from the Vall d’Hebron Research Institute, is developing an in vitro diagnostic test to improve the diagnosis of endometrial cancer using gynecological fluids as a non‑invasive biomarker source. The company’s first product is in the final prototyping stage and will move into verification and clinical validation with the new funding. MiMARK plans to accelerate clinical verification and validation and to expand R&D into additional gynecological indications, including a potential second indication for endometriosis. The company intends to strengthen collaborations with leading institutions, healthcare professionals and industry partners to advance its diagnostic platform. Financially, MiMARK closed a seed financing round totaling €4.22M that includes significant public support via the European Commission’s EIC Accelerator.

No current team members are available.